HER2, a member of the ErbB receptor tyrosine kinase family and an oncogene, is amplified or overexpressed in 15%-30% of BC cases [1] and activates oncogenic signaling pathways such as proliferation, angiogenesis, and metastasis by homodimerization or heterodimerization with other ErbB receptors, including EGFR, HER3, and HER4 [2]. Here, ERBB2 is linked to breast cancer.